http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2313923-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f08519340436545d4c81d729ca0328ed |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 |
| filingDate | 1975-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1977-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2313923-A1 |
| titleOfInvention | NEW ASSOCIATION ENABLING IN PARTICULAR ANALGESIC, MYORELAXANT, ANXIOLYTIC AND ANTI-INFLAMMATORY ACTIVITY |
| abstract | New therapeutic compsn. comprises camylofin noramidopyrin mesylate (Avapyrazone), sodium noramidopyrin mesylate monohydrate, chlormezanone and meprobamate, specifically in the ratio of 60 mg:210 mg:50 mg:50 mg respectively. Used as synergistic mixt. the compsn. has muscle relaxant, anxiolytic, analgesic and antiinflammatory activity and is esp. useful in treating pain and spasm of smooth muscle e.g. in gastrointestinal tract, of striated muscle, and of joints. A pref. dosage unit contg. 60 mg of camylofin noramidopyrin mesylate (Avapyrazone) 210 mg of sodium noramidopyrin mesylate monohydrate, 50 mg of chlormezanone and 50 mg of meprobamate, was given to adults at up to 6 dosage units daily. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10857109-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11020360-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238611-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9499480-B2 |
| priorityDate | 1975-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.